News & Views | Published:


Genomic diversity in low-risk disease: present and future

New data have confirmed the genomic diversity of low-risk prostate cancer. Improved understanding of the heterogeneity of this disease has implications for disease management and has the potential to change treatment for patients in the future.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Cooperberg, M. R. et al. The diverse genomic landscape of clinically low-risk prostate cancer. Eur. Urol. (2018).

  2. 2.

    Fraser, M. et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature 541, 359–364 (2017).

  3. 3.

    Klein, E. A. et al. Molecular analysis of low grade prostate cancer using a genomic classifier of metastatic potential. J. Urol. 197, 122–128 (2017).

  4. 4.

    Spratt, D. E. et al. Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer. J. Clin. Oncol. 36, 581–590 (2018).

  5. 5.

    Hamdy, F. C. et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl. J. Med. 375, 1415–1424 (2016).

Download references

Author information

Correspondence to R. Jeffrey Karnes.

Ethics declarations

Competing interests

R.J.K. declares research funding from GenomeDx and royalties related to Decipher. V.S. declares no competing interests.

Additional information

Related links

Decipher Genomic Resource Information Database:

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1: Identification of the diverse genomic landscape of low-risk prostate cancer.